Does Cigna Cover Jatenzo?

Cigna's Default Coverage Policy for Jatenzo

Cigna classifies Jatenzo (oral testosterone undecanoate) as a covered medication for the treatment of male hypogonadism on most commercial PPO and HMO plans, subject to prior authorization. The drug received FDA approval in March 2019 as the first oral testosterone replacement therapy that bypasses hepatic first-pass metabolism, which distinguished it from older oral androgens like methyltestosterone that carried hepatotoxicity risk.

Coverage does not mean automatic dispensing. Cigna's pharmacy benefit managers flag Jatenzo at the point of sale, requiring the prescriber to submit clinical documentation before the pharmacy can fill the prescription. This is standard for branded specialty medications in the testosterone replacement therapy (TRT) category, where multiple lower-cost generics and topical formulations exist.

Your specific plan document (the Summary of Benefits and Coverage, or SBC) controls the final answer. Employer-sponsored self-funded plans administered by Cigna can customize their formularies, meaning one Cigna member may have Jatenzo on Tier 3 while another faces a plan exclusion. Always verify your exact tier by logging into myCigna.com or calling the number on the back of your card before assuming coverage applies.

Cigna Medicare Advantage and Cigna Supplemental plans follow different formulary rules and may not cover Jatenzo at all, since testosterone products are sometimes excluded from Part D formularies. This article focuses on Cigna commercial (employer-sponsored and individual marketplace) plans.

What Formulary Tier Is Jatenzo On?

Jatenzo typically lands on a non-preferred brand or specialty tier within Cigna's formulary structure. That translates to Tier 3 or Tier 4 in most plan designs, which carry higher cost-sharing than Tier 1 (generic) or Tier 2 (preferred brand) medications.

What this means in dollars: a Tier 3 copay on a typical Cigna commercial plan ranges from $50 to $75 per 30-day supply, while Tier 4 specialty copays can reach $100 to $150 or involve coinsurance of 25% to 33% of the drug's negotiated cost. At Jatenzo's list price of roughly $900 per month, a 30% coinsurance would produce a $270 out-of-pocket charge before any manufacturer assistance.

The Endocrine Society's 2018 clinical practice guideline for testosterone therapy in men with hypogonadism recommends treatment based on confirmed low testosterone and symptoms, but does not prefer any specific formulation over another. Cigna's formulary placement reflects cost considerations, not clinical inferiority. Generic topical testosterone (1% gel) costs insurers roughly $30 to $80 per month, which explains why Cigna incentivizes topicals through lower tier placement and step therapy requirements.

If your plan uses a closed formulary and Jatenzo is excluded entirely, the prescriber can request a formulary exception. This is a separate process from standard prior authorization and requires documentation that no formulary alternative is clinically appropriate for you.

Prior Authorization Requirements

Cigna's prior authorization for Jatenzo falls into the "moderate difficulty" category. The process is not automatic, but approvals are routine when documentation is complete. Here is what the prescriber must typically submit.

Clinical criteria Cigna evaluates:

The patient must be an adult male (18 years or older) with a diagnosis of hypogonadism confirmed by two morning serum total testosterone levels below 300 ng/dL, drawn on separate days. This threshold aligns with the Endocrine Society guideline and the American Urological Association's 2018 consensus defining testosterone deficiency.

The patient must also have signs or symptoms consistent with low testosterone: fatigue, decreased libido, erectile dysfunction, loss of muscle mass, depressed mood, or increased body fat. Lab values alone, without symptoms, are usually insufficient for approval.

Documentation the prescriber needs to provide:

1. Two morning testosterone levels with dates and values
2. Clinical symptoms documented in the chart
3. An explanation of why Jatenzo specifically is requested (if step therapy applies, evidence that a topical was tried and failed or is contraindicated)
4. Relevant medical history, including any conditions contraindicating topical testosterone (severe skin disease, risk of transference to household contacts)

Turnaround time: Cigna's standard PA review takes 5 to 10 business days for non-urgent requests. Urgent (expedited) reviews, appropriate when the patient is already stabilized on Jatenzo and a lapse would cause harm, are completed within 24 to 72 hours. The prescriber initiates the request through CoverMyMeds, fax, or the Cigna provider portal.

The approval period is typically 12 months, after which reauthorization is required. At reauthorization, Cigna may ask for a recent testosterone level confirming the patient is responding to therapy.

Does Cigna Require Step Therapy Before Jatenzo?

Many Cigna plan designs impose step therapy for Jatenzo, requiring the patient to try and fail (or have a documented contraindication to) a preferred testosterone formulation first. The most common required first step is generic topical testosterone gel (AndroGel generic) or testosterone cypionate injection.

Step therapy exists because the clinical efficacy of testosterone replacement is similar across delivery methods. The key trial for Jatenzo by Swerdloff et al. (published in the Journal of Clinical Endocrinology & Metabolism, 2020; N=166) demonstrated that 87% of men achieved testosterone levels in the eugonadal range (300 to 1,100 ng/dL) at day 90. That efficacy is comparable to injectable and topical forms, so payers view Jatenzo as an alternative rather than a first-line necessity.

How to satisfy step therapy:

A 30- to 90-day trial of a topical or injectable testosterone, with documentation of the reason it did not work, usually satisfies the step. Acceptable failure reasons include:

• Inadequate testosterone response despite dose titration
• Skin irritation or allergic contact dermatitis from the gel
• Concern about transference to female partners or children (a labeled FDA black box warning on all topical testosterone products)
• Needle phobia or inability to self-inject (for injection step therapy)
• Patient preference alone is generally not sufficient

Some Cigna plans waive step therapy entirely. Not all do. If your plan's step therapy requirement is not listed on myCigna.com, your prescriber's office can call Cigna's pharmacy prior authorization line to confirm whether a step edit applies to your specific benefit.

Jatenzo Cost Breakdown With Cigna

The out-of-pocket cost for Jatenzo under Cigna coverage depends on your plan's tier placement, your deductible status, and whether you use manufacturer assistance. Here is a realistic range.

Before deductible is met: If Jatenzo falls under your pharmacy deductible, you pay the full negotiated rate (not the $900 list price, but Cigna's contracted rate, which is often $700 to $850). Once the deductible is satisfied, your copay or coinsurance kicks in.

After deductible, Tier 3: $50 to $75 per month copay is typical.

After deductible, Tier 4 with coinsurance: 25% to 33% coinsurance on the contracted rate could mean $175 to $280 per fill.

With manufacturer savings card: Tolmar Pharmaceuticals (Jatenzo's manufacturer) offers a copay savings program for commercially insured patients. Eligible patients may pay as little as $0 per month, with the card covering up to a set annual maximum (historically $6,000 to $9,000 per year). The savings card cannot be used with government insurance (Medicare, Medicaid, Tricare, VA). Check the manufacturer's website for current terms, as savings programs change annually.

Accumulator adjuster warning: Some Cigna plans use copay accumulator adjustment programs that prevent manufacturer copay assistance from counting toward your annual out-of-pocket maximum. If your plan has an accumulator, you could exhaust the savings card and still face full coinsurance for the remainder of the year. Ask your Cigna benefits specialist whether your plan applies accumulator adjustments to specialty copay cards.

How to Appeal a Cigna Denial of Jatenzo

A denial is not the end. Cigna provides a structured appeal pathway, and denials for TRT medications are frequently overturned when the appeal includes complete clinical documentation.

Level 1: Internal Appeal. You or your prescriber must file within 180 days of the denial. Submit a written appeal letter that addresses the specific reason for denial stated in Cigna's adverse determination letter. If the denial was for insufficient step therapy documentation, include records proving the prior trial. If the denial cited lack of medical necessity, include peer-reviewed evidence supporting oral testosterone for your specific clinical situation. Cigna must respond within 30 calendar days for standard appeals or 72 hours for urgent/expedited appeals.

Level 2: Second Internal Appeal. If Level 1 is upheld, Cigna allows a second internal review by a different clinical reviewer. The same documentation rules apply. You may add new evidence not included in the first appeal.

External Independent Review (IRO). After exhausting internal appeals (or simultaneously, in some states), you can request an external review by an independent review organization. The IRO is a third-party panel of physicians not employed by Cigna. Under the Affordable Care Act, all commercial plans must offer external review. The IRO decision is binding on Cigna. External reviews are free to the member.

Practical tips for a successful appeal:

Your prescriber's letter of medical necessity is the most important document. It should reference the Endocrine Society's clinical practice guideline, cite the patient's specific lab values and symptoms, and explain why Jatenzo is medically necessary over alternatives. A letter that states "patient prefers oral" is weaker than one that states "patient's 6-year-old daughter experienced virilization symptoms from transference of topical testosterone, necessitating a non-transdermal formulation." Specificity wins appeals.

Include the Swerdloff et al. study showing Jatenzo's clinical efficacy and safety profile as supporting evidence. The study documented that oral testosterone undecanoate achieved and maintained eugonadal testosterone levels without the supraphysiological spikes associated with intramuscular injections.

Jatenzo vs. Other Testosterone Formulations on Cigna

Understanding where Jatenzo fits in Cigna's formulary relative to other TRT options helps set expectations about coverage and cost.

Generic testosterone cypionate injection (Tier 1, $10 to $30/month): Cigna's most preferred option. Requires intramuscular injection every 1 to 2 weeks. Peak-and-trough testosterone fluctuations are a known limitation. The Endocrine Society guideline notes that some patients experience mood swings or energy dips in the days before the next injection.

Generic testosterone gel 1% (Tier 1-2, $30 to $80/month): Applied daily to shoulders or upper arms. Effective and well-studied, but carries an FDA black box warning for secondary exposure (transference) risk.

Natesto (testosterone nasal gel) (Tier 3-4, $500 to $600/month): Applied intranasally three times daily. Less transference risk but frequent dosing. Often treated similarly to Jatenzo by Cigna (requires PA, non-preferred tier).

Jatenzo (oral testosterone undecanoate) (Tier 3-4, $900/month list): Twice-daily oral capsule taken with food. No transference risk, no injections. The convenience and safety profile explain patient demand despite higher cost.

Testosterone pellets (Testopel) (variable coverage): Subcutaneous implant every 3 to 6 months. Often covered as a medical benefit rather than pharmacy benefit, meaning different prior authorization pathways.

Cigna's tiering reflects a straightforward cost hierarchy. The cheapest effective option gets preferred placement. A 2023 retrospective analysis published in the Journal of the Endocrine Society found no significant difference in symptom resolution rates between injectable, topical, and oral testosterone when dosed appropriately, which supports payers' position that step therapy is clinically reasonable even if less convenient for the patient.

Clinical Profile of Jatenzo: What Makes It Different

Jatenzo's clinical profile matters for insurance discussions because the drug's unique characteristics create legitimate medical necessity arguments that go beyond preference.

The Swerdloff et al. key trial enrolled 166 hypogonadal men and demonstrated that oral testosterone undecanoate (Jatenzo) restored eugonadal testosterone levels in 87% of subjects by day 90. The drug uses a self-emulsifying delivery system absorbed via the intestinal lymphatic pathway, bypassing hepatic first-pass metabolism. This is a meaningful pharmacological distinction from methyltestosterone, the older oral androgen that caused dose-dependent liver toxicity and is rarely prescribed today.

Blood pressure increases were the most common adverse finding in the trial. Systolic blood pressure rose by an average of 3 to 5 mmHg in the Jatenzo group compared to the hypogonadal control arm. The FDA label includes a warning about cardiovascular risk, consistent with the class-wide testosterone REMS considerations. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, examined cardiovascular outcomes with topical testosterone and found no increased risk of major adverse cardiac events compared to placebo in men with pre-existing cardiovascular risk factors. While TRAVERSE studied topical rather than oral testosterone, the findings contributed to a broader reassessment of cardiovascular risk across all testosterone formulations.

Jatenzo's twice-daily dosing with food is a clinical consideration. Testosterone absorption is dependent on co-ingestion with a meal containing at least 20 grams of fat. Patients who skip meals or eat low-fat diets may have inconsistent absorption, a point Cigna reviewers sometimes raise when evaluating medical necessity.

Hematocrit monitoring is standard for all TRT formulations, including Jatenzo. The Endocrine Society recommends checking hematocrit at baseline, at 3 to 6 months, and then annually. If hematocrit exceeds 54%, dose reduction or discontinuation is recommended to reduce thromboembolic risk (Endocrine Society guideline, 2018).

Common Reasons Cigna Denies Jatenzo (and How to Prevent Them)

Forewarned is forearmed. These are the most frequent denial reasons and how prescribers can avoid them.

Only one testosterone level submitted. Cigna requires two levels drawn on separate mornings. A single low reading triggers a denial. Have the second level drawn before submitting the PA.

Testosterone level drawn in the afternoon. Testosterone follows a circadian rhythm, peaking between 7:00 and 10:00 AM. Afternoon values are physiologically lower and may not reflect true deficiency. Cigna's criteria specify morning draws, and reviewers will reject afternoon values.

No symptoms documented. A lab value below 300 ng/dL alone is not enough. The chart note accompanying the PA must list specific symptoms. "Low T symptoms" is vague. "Decreased libido for 8 months, erectile dysfunction unresponsive to PDE5 inhibitors, and fatigue interfering with occupational performance" is specific and approvable.

Step therapy not addressed. If the plan requires step therapy and the PA does not mention prior treatment, the claim is auto-denied. Even if the patient has a contraindication to topicals, that contraindication must be stated in the PA request.

Off-label use. Jatenzo is FDA-approved only for male hypogonadism. Requests for female testosterone therapy, athletic performance, or "anti-aging" in men with normal testosterone levels will be denied. Cigna does not cover Jatenzo for weight loss, as testosterone replacement is not indicated for obesity treatment regardless of its effects on body composition.